🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies

RecruitingNAAges 18 Years - anyAllFondation Hôpital Saint-Joseph
NCT06061705 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Epidermoid Carcinoma of the Upper Aerodigestive Tract (CEVADS) is the 6th most common cancer worldwide. Despite current therapies (radiotherapy, surgery and chemotherapy), cancers of the Upper Aerodigestive Tract (UAT) have a poor prognosis, with a 10-year survival rate of no more than 20%. For recurrent or metastatic CEVADS, the therapeutic arsenal, based for many years on chemotherapy and anti-EGFR (Epidermal Growth Factor Receptor) agents, has been enriched by a new therapeutic class: PD-1 inhibitors. For CEVADS, PD-1 inhibitors have been approved for second-line treatment of nivolumab for over a year, and are now used in first-line treatment of pembrolizumab. The results of this therapeutic class in CEVADS are not as spectacular as for melanoma or bronchial cancer. Indeed, only 20% of patients have a favorable response, compared with half who experience disease progression. This lo

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients aged ≥ 18 years * Patients with histologically confirmed CEVADS involving the oral cavity, oropharynx, hypopharynx or larynx * Pre-treated patients with a first recurrence (locoregional or metastatic) who are candidates for immunotherapy * Patient affiliated to a health insurance plan * French-speaking patient * Patient with free, informed and written consent Exclusion Criteria: * Patients with a contraindication to immunotherapy (transplant patients) * Pregnant or breast-feeding patients * Patient under guardianship or curatorship * Patient under court protection * Patient deprived of liberty
💊

What it tests

  • Tumor Biopsy
📍

Where

3 sites
Hôpital Saint-Joseph
Paris, France
Hôpital Bichat
Paris, France
Hôpital Saint-Louis
Paris, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy